Abstract：
UNASSIGNED: Most patients with pancreatic cancer who have undergone surgical resection eventually develop disease recurrence. This study aimed to investigate whether there is evidence to support routine surveillance after pancreatic cancer surgery, with a secondary aim of analyzing the implementation of surveillance strategies in the Nordic countries.
UNASSIGNED: A scoping review was conducted to identify clinical practice guidelines globally and research studies relating to surveillance after pancreatic cancer resection. This was followed by a survey among 20 pancreatic units from four Nordic countries to assess their current practice of follow-up for operated patients.
UNASSIGNED: Altogether 16 clinical practice guidelines and 17 research studies were included. The guidelines provided inconsistent recommendations regarding postoperative surveillance of pancreatic cancer. The clinical research data were mainly based on retrospective cohort studies with low level of evidence and lead-time bias was not addressed. Active surveillance was recommended in Sweden and Denmark, but not in Norway beyond the post-operative/adjuvant period. Finland had no national recommendations for surveillance. The Nordic survey revealed a wide variation in reported practice among the different units. About 75% (15 of 20 units) performed routine postoperative surveillance. Routine CA 19-9 testing was used by 80% and routine CT by 67% as part of surveillance. About 73% of centers continued follow-up until 5 years postoperatively.
UNASSIGNED: Evidence for routine long-term (i.e. 5 years) surveillance after pancreatic cancer surgery remains limited. Most pancreatic units in the Nordic countries conduct regular follow-up, but protocols vary.
UNASSIGNED: A scoping review was conducted to identify clinical practice guidelines globally and research studies relating to surveillance after pancreatic cancer resection. This was followed by a survey among 20 pancreatic units from four Nordic countries to assess their current practice of follow-up for operated patients.
UNASSIGNED: Altogether 16 clinical practice guidelines and 17 research studies were included. The guidelines provided inconsistent recommendations regarding postoperative surveillance of pancreatic cancer. The clinical research data were mainly based on retrospective cohort studies with low level of evidence and lead-time bias was not addressed. Active surveillance was recommended in Sweden and Denmark, but not in Norway beyond the post-operative/adjuvant period. Finland had no national recommendations for surveillance. The Nordic survey revealed a wide variation in reported practice among the different units. About 75% (15 of 20 units) performed routine postoperative surveillance. Routine CA 19-9 testing was used by 80% and routine CT by 67% as part of surveillance. About 73% of centers continued follow-up until 5 years postoperatively.
UNASSIGNED: Evidence for routine long-term (i.e. 5 years) surveillance after pancreatic cancer surgery remains limited. Most pancreatic units in the Nordic countries conduct regular follow-up, but protocols vary.
摘要：
■大多数接受手术切除的胰腺癌患者最终会出现疾病复发。本研究旨在调查是否有证据支持胰腺癌手术后的常规监测，次要目的是分析北欧国家监测战略的实施情况。
■进行了范围审查，以确定全球临床实践指南和与胰腺癌切除术后监测相关的研究。随后，对来自四个北欧国家的20个胰腺单位进行了一项调查，以评估他们目前对手术患者进行随访的做法。
■共纳入16项临床实践指南和17项研究。该指南对胰腺癌术后监测提供了不一致的建议。临床研究数据主要基于回顾性队列研究，证据水平低，未解决前置时间偏差。瑞典和丹麦建议积极监测，但不在挪威超过手术/辅助期。芬兰没有关于监测的国家建议。北欧调查显示，不同单位之间的报告实践差异很大。大约75％（20个单位中的15个）进行了常规的术后监测。作为监测的一部分，80%使用常规CA19-9检测，67%使用常规CT。约73%的中心持续随访至术后5年。
■胰腺癌手术后常规长期（即5年）监测的证据仍然有限。北欧国家的大多数胰腺单位进行定期随访，但是协议各不相同。
■进行了范围审查，以确定全球临床实践指南和与胰腺癌切除术后监测相关的研究。随后，对来自四个北欧国家的20个胰腺单位进行了一项调查，以评估他们目前对手术患者进行随访的做法。
■共纳入16项临床实践指南和17项研究。该指南对胰腺癌术后监测提供了不一致的建议。临床研究数据主要基于回顾性队列研究，证据水平低，未解决前置时间偏差。瑞典和丹麦建议积极监测，但不在挪威超过手术/辅助期。芬兰没有关于监测的国家建议。北欧调查显示，不同单位之间的报告实践差异很大。大约75％（20个单位中的15个）进行了常规的术后监测。作为监测的一部分，80%使用常规CA19-9检测，67%使用常规CT。约73%的中心持续随访至术后5年。
■胰腺癌手术后常规长期（即5年）监测的证据仍然有限。北欧国家的大多数胰腺单位进行定期随访，但是协议各不相同。
